Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells

In Vivo

Volumn 24, Issue 4, 2010, Pages 489-493

  Rubenstein, Marvin ^a,b,c   Guinan, Patrick ^b,c,d  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Department of Ambulatory and Community Health   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Prostate cancer; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PROTEIN BCL 2;

AGAR GEL ELECTROPHORESIS; ARTICLE; BINDING SITE; CELL CULTURE; CELL STRAIN LNCAP; IN VITRO STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 77955887673     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Steiner MS, Anthony CT, Lu Y and Holt JT: Antisense c-myc retroviral suppresses established human prostate cancer. Hum Gene Ther 9: 747-755, 1998. (Pubitemid 28200630)
2. Walder RY and Walder JA: Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85: 5011-5015, 1988.
3. Felsenfeld G and Miles HT: Formation of a three-stranded polynucleotide molecule. J Amer Chem Soc 79: 2023-2024, 1957.
4. Durland RH, Kessler DJ and Hogan M: Antiparallel triplex formation at physiological pH. In: Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. Wickstrom E (ed.). New York: Wiley-Liss, pp. 219-226, 1991.
5. Rubenstein M, Tsui P and Guinan P: Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Clin Pharmacol 28: 515-518, 2006.
6. Rubenstein M, Tsui P and Guinan P: Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate cancer. Med Oncol 24: 372-378, 2007.
7. Rubenstein M, Tsui P and Guinan P: Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparisons between combination therapies employing bispecific oligonucleotides with either rapamycin or paclitaxel. Med Oncol 26: 124-130, 2009.
8. Rubenstein M, Slobodskoy L, Mirochnik Y and Guinan P: Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol. Med Oncol 20: 29-35, 2003.
9. Tsui P, Rubenstein M and Guinan P: Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model. Med Oncol 21: 339-348, 2004. (Pubitemid 40065485)
10. Rubenstein M, Tsui P and Guinan P: Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses 65: 905-907, 2005.
11. Rubenstein M, Tsui P and Guinan P: Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate tumors. Med Oncol 24: 189-196, 2007. (Pubitemid 350135970)
12. Rubenstein M, Tsui P and Guinan P: Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity towards proteins associated with autocrine regulated growth and BCL-2. Med Oncol 25: 182-186, 2008.
13. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B and Gleave M: Novel bispecific antisense oligonucleotides inhibiting both BCL-2 and BCL-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proceedings AACR 45: Abstract #2930, 2004.
14. Takahara K, Muramaki M, Li D, Cox ME and Gleave ME: Insulin-like growth factor-binding protein-5 (IGFBP5) supports prostate cancer cell proliferation. J Urol 181: Abstract #184, 2009.
15. Rubenstein M, Mirochnik Y, Bremer E, George D, Freilich L and Guinan P: Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate carcinoma cells. Proceedings AACR 43: Abstract #590, 2002.
16. Rubenstein M, Mirochnik Y, Chow P and Guinan P: Antisense oligonucleotide intralesional therapy of human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 62: 194-200, 1996. (Pubitemid 26231490)
17. Rubenstein M, Anderson KM, Tsui P and Guinan P: Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone-insensitive prostate cancer. Med Hypoth 67: 1375-1380, 2006.
18. Lee B-S, Fujita M, Ljubimova JY and Holler E: Delivery of antisense oligonucleotides and transferrin receptor antibody in vitro and in vivo using a new multifunctional drug delivery system based on polymalic acid. Proc AACR 45: Abstract #647, 2004.
19. Santhakumaran L, Thomas T and Thomas TJ: Nanoparticle formation in an antisense oligonucleotide by polyproplin-imine dendrimers: facilitation of cellular uptake and intracellular stability. Proc AACR 45: Abstract #2938, 2004.